American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2020, 8(5), 137-139
DOI: 10.12691/ajmcr-8-5-7
Open AccessCase Report

Portopulmonary Hypertension with Liver Cirrhosis

Tyler Kemnic1, 2, , James Choi1, 2, Manel Boumegouas1, 2 and Shaurya Srivastava3

1Michigan State University Department of Medicine

2Sparrow Hospital

3Michigan State University College of Osteopathic Medicine

Pub. Date: March 24, 2020

Cite this paper:
Tyler Kemnic, James Choi, Manel Boumegouas and Shaurya Srivastava. Portopulmonary Hypertension with Liver Cirrhosis. American Journal of Medical Case Reports. 2020; 8(5):137-139. doi: 10.12691/ajmcr-8-5-7


A 49-year-old male with a past medical history of smoking (20 pack-years), 25 years of daily drinking, type 2 diabetes, alcoholic liver cirrhosis, hyperlipidemia, and hypertension presented with a complaint of weakness, shortness of breath and dizziness. Three days prior the patient completed an echocardiogram that revealed tricuspid regurgitation with right ventricular dilation and a right ventricular systolic pressure of 116 mmHg. Cardiology was consulted and completed right heart catheterization, VQ scan, as well as autoimmune and infectious investigations. The patient was diagnosed with Portopulmonary Hypertension (PPHTN) complicated by liver cirrhosis. Treatment was initiated with sildenafil, amlodipine, aspirin and continuous oxygen with scheduled outpatient appointments for both IV prostacyclin treatment and pre-liver transplant (LT) evaluation.

Portopulmonary hypertension cardiology cirrhosis pulmonary

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Saleemi S. Portopulmonary hypertension. Ann Thorac Med. 2010; 5(1): 5-9.
[2]  Aldenkortt F, Aldenkortt M, Caviezel L, Waeber JL, Weber A, Schiffer E. Portopulmonary hypertension and hepatopulmonary syndrome. World J Gastroenterol. 2014; 20(25): 8072-8081.
[3]  Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008; 48(1): 196-203.
[4]  Colle, I. O., Moreau, R., Godinho, E., Belghiti, J., Ettori, F., Cohen‐Solal, A., Mal, H., Bernuau, J., Marty, J., Lebrec, D., Valla, D. and Durand, F. (2003), Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology, 37: 401-409.
[5]  Provencher S, Herve P, Jaı¨s X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
[6]  Does Portopulmonary Hypertension Impede Liver Transplantation in Cirrhotic Patients? A French Multicentric Retrospective Study. Reymond M, Barbier L, Salame E, Besh C, Dumortier J, Pageaux GP, Bureau C, Dharancy S, Vanlemmens C, Abergel A, Woehl Jaegle ML, Magro P, Patat F, Laurent E, Perarnau JM Transplantation. 2018; 102(4): 616.
[7]  Takashi Onoe, Asuka Tanaka, Kohei Ishiyama, Kentaro Ide, Hirotaka Tashiro & Hideki Ohdan Surgical Case Reports volume 4, Article number: 15 (2018).
[8]  Radhika Zopey, Irawan Susanto, Igor Barjaktarevic, and Tisha Wang, “Transition from Hepatopulmonary Syndrome to Portopulmonary Hypertension: A Case Series of 3 Patients,” Case Reports in Pulmonology, vol. 2013, Article ID 561870, 5 pages, 2013.